Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study-Reference-Cited by-同舟云学术

Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study

Published:2019-08-01 Issue:9 Volume:51 Page:1649-1657
ISSN:0301-1623
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Alshahawey Mona,Shaheen Sara M.^ORCID,Elsaid Tamer,Sabri Nagwa Ali

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

http://link.springer.com/content/pdf/10.1007/s11255-019-02243-w.pdf

Reference52 articles.

1. Modaresi A, Nafar M, Sahraei Z (2015) Oxidative stress in chronic kidney disease. Iran J Kidney Dis 9(3):165–179

2. Locatelli F, Marcelli D, Conte F, Amico DM, Del Vecchio L, Limido A, Malberti F, Spotti D (2000) Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 15(90005):69–80

3. Bossola M, Tazza L (2015) Wishful thinking: the surprisingly sparse evidence for a relationship between oxidative stress and cardiovascular disease in hemodialysis patients. Semin Dial 28(3):224–230

4. Kielstein JT, FroÈlich JC, Haller H, Fliser D (2001) ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol Dial Transplant 16(9):1742–1745

5. El-Mesallamy HO, Hamid SGA, Gad MZ (2008) Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by l-arginine intake. Kidney Blood Press Res 31(3):189–195

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cholecalciferol effect on oxidative stress and novel predictors of inflammation in hemodialysis patients: a prospective randomized trial;Future Journal of Pharmaceutical Sciences;2024-09-09

2. Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials;Annals of Medicine;2024-05-13

3. Heparin-Mediated Extracorporeal Low-Density Lipoprotein Precipitation Apheresis for Treating Peripheral Arterial Disease in Patients with Chronic Kidney Disease;Journal of Clinical Medicine;2024-02-16

4. Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease;Scientific Reports;2023-08-18

5. Effect of febuxostat on the level of malondialdehyde‐modified low‐density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study;Clinical Cardiology;2023-03-29